IDO2-IN-1

IDO2-IN-1 is an orally active and potent Indoleamine 2,3-dioxygenase 2 ( IDO2 ) inhibitor with an IC 50 value of 112 nM. IDO2-IN-1 can be used for inflammatory autoimmunity research In Vitro IDO2-IN-1 (compound 22) shows stronger inhibition on IDO2 (IC 50 =112 nM) over IDO1 (IC 50 =411 nM). IDO2-IN-1 inhibits hIDO1 expression (EC 50 =633 nM) in HeLa cell-based IDO1/kynurenine assay, co-incubated with hIFN-γ (100 ng/mL final concentration), which is used for producing N-formylkynurenine. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: HeLa cells line expressing hIDO1 induced by IFN-γ Concentration: 1 nM-0.1 mM Incubation Time: 48 hours Result: Showed additional potency against IDO1 with an EC 50 value of 633 nM. In Vivo The Adjuvant arthritis (AA) model and Collagen-induced arthritis (CIA) model have similar pathogenesis and pathological characteristics to human rheumatoid arthritis (RA). IDO2-IN-1 (compound 22) (100 mg/kg; p.o.; once dose) exhibits excellent anti-inflammatory activity, higher than naproxen, a prescription drug reducing pain, swelling, and joint stiffness from arthritis . IDO2-IN-1 (25, 50, 100 mg/kg; i.p.; once daily, for 19 d) exhibits excellent inhibitory effect on mice paw swelling, shows efficacy in a collagen-induced arthritis model in mice . IDO2-IN-1 (30, 60, 120 mg/kg; i.p.; once daily, for 15 d) inhibits joint inflammation and displays potential effect in autoimmune arthritis improvement . Pharmacokinetic Profile in Rat Route Dose (mg/kg) T 1/2/sub> (h) T max (h) C max (ng/mL) AUC (0-∞) (h•ng/mL) CL (mL/h/kg) V z (mL/kg) MRT (0-∞) (h) F (%) i.v. 1 0.69 / / 375.1 2673 2675 0.55 / p.o. 10 2.02 0.75 153.8 670.5 / / 7.48 17.87 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Xylene-induced ear swelling mouse model (ICR mice, male, 6 weeks old) Dosage: 100 mg/kg Administration: Oral gavage; once dose; evenly coated right ear with 25 μL of xylene after 1 h treatment Result: Significantly relieved mouse ear swelling with a high swelling inhibition rate of 65.32%. Animal Model: Collagen-induced arthritis (CIA) mice model (DBA/1J mice, male, 6 weeks old) Dosage: 25, 50, 100 mg/kg Administration: Intraperitoneal injection; once daily; 19 days, began on day 56 after collagen induced Result: Decreased the expression of inflammatory cytokines IL-18 and IL-33. Reduced inflammation and cartilage and bone erosions symptoms. Animal Model: Adjuvant arthritis (AA) rat model (Sprague-Dawley rats, male, 180 ± 20 g) Dosage: 30, 60, 120 mg/kg Administration: Intraperitoneal injection; once daily; 15 days, began on day 21 after chondrex induced Result: Significantly reduced IL-6 and TNF-α levels. Decreased synovial hyperplasia accompanied by inflammatory cell infiltration, pannus formation, and bone erosion of cartilage in a dose-dependent manner. Form:Solid IC50& Target:IDO1 411 nM (IC 50 ) IDO2 112 (IC 50 )

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet